[Role of glycemic control on preventing diabetic macroangiopathy and its therapeutic guidance].
Recent clinical trials targeting the subjects with type 1 and 2 diabetes have proved that glycemic control was closely related with the incidence of macro- and microangiopathy. The landmark studies such as DCCT, Kumamoto study and UKPDS provided the evidence that a strict glycemic control could prevent a development of microangiopathy. Furthermore, the long-term follow-up studies such as DCCT/EDIC and UKPDS 80 demonstrated that more early intervention was important to obtain a sufficient prevention of macroangiopathy. However, the concrete target of glycemic control to prevent macroangiopathy is still controversial. In this article, we reviewed recent clinical trials from the viewpoint of glycemic control and prevention of diabetic macroangiopathy.